Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Placebo-controlled prospective randomized phase III study to investigate the
antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of
the midgut